Format

Send to

Choose Destination
J Cell Biol. 2012 Oct 1;199(1):15-9. doi: 10.1083/jcb.201205167.

The genesis of Zelboraf: targeting mutant B-Raf in melanoma.

Author information

1
Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA.

Abstract

The protein kinase B-Raf is a critical component of the Ras/MAPK signaling pathway. An oncogenic B-Raf mutation that constitutively activates the kinase was identified in ~50% of melanoma patients and in other cancers. A structure-guided drug discovery approach enabled the development of Zelboraf, a targeted inhibitor of oncogenic B-Raf. This drug has been used successfully in the clinic to treat metastatic melanoma patients harboring B-Raf mutations.

PMID:
23027900
PMCID:
PMC3461519
DOI:
10.1083/jcb.201205167
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center